Literature DB >> 22437814

Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.

John C Lipscomb1, Sami Haddad, Torka Poet, Kannan Krishnan.   

Abstract

Physiologically-based pharmacokinetic (PBPK) modeling offers a scientifically-sound framework for integrating mechanistic data on absorption, distribution, metabolism and elimination to predict the time-course of parent chemical, metabolite(s) or biomarkers in the exposed organism. A major advantage of PBPK models is their ability to forecast the impact of specific mechanistic processes and determinants on the tissue dose. In this regard, they facilitate integration of data obtained with in vitro and in silico methods, for making predictions of the tissue dosimetry in the whole animal, thus reducing and/or refining the use of animals in pharmacokinetic and toxicity studies. This chapter presents the principles and practice of PBPK modeling, as well as the application of these models in toxicity testing and health risk assessments.

Entities:  

Mesh:

Year:  2012        PMID: 22437814     DOI: 10.1007/978-1-4614-3055-1_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment.

Authors:  John M Harrold; Anson K Abraham
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-12       Impact factor: 2.745

2.  Deterministic models of inhalational anthrax in New Zealand white rabbits.

Authors:  Bradford Gutting
Journal:  Biosecur Bioterror       Date:  2014-02-14

3.  Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.

Authors:  Pankaj K Sethi; Catherine A White; Brian S Cummings; Ronald N Hines; Srinivasa Muralidhara; James V Bruckner
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

4.  Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits.

Authors:  Panteleimon D Mavroudis; Helen E Hermes; Donato Teutonico; Thomas G Preuss; Sebastian Schneckener
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

Review 5.  The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development.

Authors:  Zhengying Zhou; Jinwei Zhu; Muhan Jiang; Lan Sang; Kun Hao; Hua He
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

6.  Circulating persistent organic pollutants and body fat distribution: Evidence from NHANES 1999-2004.

Authors:  Geng Zong; Philippe Grandjean; Hongyu Wu; Qi Sun
Journal:  Obesity (Silver Spring)       Date:  2015-08-03       Impact factor: 5.002

Review 7.  Advancing human health risk assessment: integrating recent advisory committee recommendations.

Authors:  Michael Dourson; Richard A Becker; Lynne T Haber; Lynn H Pottenger; Tiffany Bredfeldt; Penelope A Fenner-Crisp
Journal:  Crit Rev Toxicol       Date:  2013-07       Impact factor: 5.635

8.  Use of physiologically-based pharmacokinetic modeling to simulate the profiles of 3-hydroxybenzo(a)pyrene in workers exposed to polycyclic aromatic hydrocarbons.

Authors:  Roberto Heredia Ortiz; Anne Maître; Damien Barbeau; Michel Lafontaine; Michèle Bouchard
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

Review 9.  Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds.

Authors:  Eleonore Fröhlich; Annalisa Mercuri; Shengqian Wu; Sharareh Salar-Behzadi
Journal:  Front Pharmacol       Date:  2016-06-24       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.